VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Herbst on a Smoking Cessation Trial for Lung Cancer

Roy S. Herbst, MD, PhD
Published: Tuesday, May 30, 2017



Roy S. Herbst, MD, PhD, ensign professor of Medicine, professor of Pharmacology, chief of Medical Oncology, associate director for Translational Research, Yale Cancer Center and Smilow Cancer Hospital, discusses a smoking cessation trial for patients with lung cancer.

Smoking is the cause of lung cancer in over 80% of patients, explains Herbst. When people come in to be screened it is an important time to discusses the importance of smoking cessation.

It is being investigated if positive reinforcement has more of an impact on a patient looking to quit smoking, states Herbst.
 


Roy S. Herbst, MD, PhD, ensign professor of Medicine, professor of Pharmacology, chief of Medical Oncology, associate director for Translational Research, Yale Cancer Center and Smilow Cancer Hospital, discusses a smoking cessation trial for patients with lung cancer.

Smoking is the cause of lung cancer in over 80% of patients, explains Herbst. When people come in to be screened it is an important time to discusses the importance of smoking cessation.

It is being investigated if positive reinforcement has more of an impact on a patient looking to quit smoking, states Herbst.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x